Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

From spinning out Takeda’s China assets to acquiring South Korea’s Hugel, CBC is building a global M&A engine with execution at its core.

That makes it the second-largest biotech IPO this year, after Acelyrin raised $540 million in May. The biotech is developing a radiopharmaceutical called RYZ101 in phase 3 trials for ...

After hitting a record high in 2021, the number of biotech IPOs have fallen to a yearly average in the 20s, with most successful entries in the last few quarters involving companies with mid- to ...

Endiya actively assists portfolio companies with product rollouts, customer acquisition hiring, and preparing for future ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

Discover how PomDoctor Limited aims to revolutionize China's telehealth industry with a $15M IPO, despite facing stiff ...